Atai Life Sciences N.V. (ATAI)

NASDAQ: ATAI · IEX Real-Time Price · USD

1.480

0.00 (0.00%)

At close: Jul 19, 2024, 4:00 PM

1.520

+0.040 (2.70%)

Pre-market: Jul 22, 2024, 7:05 AM EDT

Atai Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.28	0.31	0.23	20.38	0	0
Revenue Growth (YoY)	2.97%	34.76%	-98.86%	-	-	-
Gross Profit	0.28	0.31	0.23	20.38	0	0
Selling, General & Admin	62.17	63.58	70.35	92.75	80.73	5.09
Research & Development	54.45	62.2	74.31	47.96	11.41	3.08
Other Operating Expenses	0	0	0.36	15.48	12.02	9.67
Operating Expenses	116.62	125.79	145.02	156.18	104.16	17.85
Operating Income	-116.34	-125.47	-144.79	-135.81	-104.16	-17.85
Interest Expense / Income	2.72	2.66	0.92	0	0	0
Other Expense / Income	-86.11	-88.92	0.45	35.99	65.38	-3.71
Pretax Income	-32.96	-39.21	-146.16	-171.8	-169.54	-14.14
Income Tax	0.85	1.02	6.23	-3.99	0.31	0
Net Income	-33.8	-40.22	-152.39	-167.81	-169.84	-14.14
Shares Outstanding (Basic)	159	159	156	138	93	87
Shares Outstanding (Diluted)	159	159	156	138	93	87
Shares Change	1.99%	2.00%	12.62%	48.64%	7.34%	-
EPS (Basic)	-0.21	-0.25	-0.98	-1.21	-1.83	-0.16
EPS (Diluted)	-0.24	-0.25	-0.98	-1.21	-1.83	-0.16
Free Cash Flow	-85.73	-84.71	-105.49	-64.37	-20.83	-7.87
Free Cash Flow Per Share	-0.54	-0.53	-0.68	-0.47	-0.22	-0.09
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-42000.72%	-39958.92%	-62140.34%	-666.49%	-	-
Profit Margin	-12203.25%	-12810.19%	-65401.29%	-823.56%	-	-
Free Cash Flow Margin	-30950.18%	-26977.07%	-45275.11%	-315.93%	-	-
EBITDA	-29.43	-35.85	-145.07	-171.75	-169.51	-14.13
EBITDA Margin	-10624.91%	-11417.20%	-62259.66%	-842.90%	-	-
Depreciation & Amortization	0.8	0.7	0.17	0.05	0.02	0.01
EBIT	-30.23	-36.55	-145.23	-171.8	-169.54	-14.14
EBIT Margin	-10914.80%	-11640.76%	-62331.76%	-843.13%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).